---
title: "Tectonic Therapeutic | 8-K: FY2026 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285617697.md"
datetime: "2026-05-07T20:53:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285617697.md)
  - [en](https://longbridge.com/en/news/285617697.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285617697.md)
generator: "portal-rs"
---

# Tectonic Therapeutic | 8-K: FY2026 Q1 Revenue: USD 0

Revenue: As of FY2026 Q1, the actual value is USD 0.

EPS: As of FY2026 Q1, the actual value is USD -1.34, missing the estimate of USD -1.1663.

EBIT: As of FY2026 Q1, the actual value is USD -29.47 M.

#### Cash Position

As of March 31, 2026, cash and cash equivalents were $236.9 million, a decrease from $253.8 million as of December 31, 2025.

#### Operating Expenses

For the three months ended March 31, 2026, total operating expenses were $27.301 million, compared to $18.298 million for the three months ended March 31, 2025. **Research and Development Expenses**: These expenses were $20.871 million for the three months ended March 31, 2026, an increase from $13.036 million for the same period in 2025. **General and Administrative Expenses**: These expenses amounted to $6.430 million for the three months ended March 31, 2026, up from $5.262 million for the corresponding period in 2025.

#### Net Loss

For the three months ended March 31, 2026, Tectonic Therapeutic, Inc. reported a net loss of - $25.241 million, compared to a net loss of - $15.906 million for the three months ended March 31, 2025.

#### Balance Sheet Data

-   **Working Capital**: Working capital was $226.933 million as of March 31, 2026, down from $247.693 million as of December 31, 2025.
-   **Total Assets**: Total assets were $246.577 million as of March 31, 2026, compared to $261.038 million as of December 31, 2025.
-   **Total Stockholders’ Equity**: Total stockholders’ equity stood at $230.417 million as of March 31, 2026, a decrease from $251.329 million as of December 31, 2025.

#### Outlook / Guidance

Tectonic Therapeutic, Inc. anticipates its cash and cash equivalents will provide a cash runway into Q4 2028, supporting Phase 2 readouts for TX45 in PH-HFpEF and PH-ILD, and the clinical progression of TX2100 for HHT. The company expects topline results for the TX45 APEX Phase 2 trial in late Q4 2026 or early Q1 2027, and for the TX2100 Phase 1a trial by the end of Q3 2026. Tectonic Therapeutic, Inc. also launched the TX45 ALPINE Phase 2 clinical trial for PH-ILD and plans to advance TX2100 into a Phase 2 trial in early 2027, subject to favorable safety and pharmacokinetic results.

### Related Stocks

- [TECX.US](https://longbridge.com/en/quote/TECX.US.md)

## Related News & Research

- [FN: Record revenue and EPS growth in Q4 and FY26, with strong outlook for Q1 FY27](https://longbridge.com/en/news/296142824.md)
- [MRCY: Record bookings, backlog, and revenue drive improved outlook and strong FY26 performance](https://longbridge.com/en/news/296265272.md)
- [Skye Bio amends 8-K to set Aug. 24 effective date for reverse stock split](https://longbridge.com/en/news/296471274.md)
- [JKHY: Record revenue and margin growth in 2026, with strong outlook for 2027](https://longbridge.com/en/news/296268676.md)
- [Vital Farms amends 8-K to add missing Item 5.03 in EDGAR header](https://longbridge.com/en/news/296122466.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**